The high price of anticancer drugs: origins, implications, barriers, solutions

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

(2017) Qiushi Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

The Rising Price of Cancer Drugs—A New Old Problem?

(2017) Vinay Prasad et al.   JAMA Oncology

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

(2016) N. Cherny et al.   ANNALS OF ONCOLOGY

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States

(2016) G. H. Jones et al.   BLOOD

‘Government Patent Use’: A Legal Approach To Reducing Drug Spending

(2016) Amy Kapczynski et al.   HEALTH AFFAIRS

The High Cost of Prescription Drugs in the United States

(2016) Aaron S. Kesselheim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices

(2016) Sham Mailankody et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy

(2016) Alana Biggers et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).

(2016) David Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2016) Ben Y. Durkee et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia

(2016) Aaron N. Winn et al.   JOURNAL OF CLINICAL ONCOLOGY

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer

(2016) Scott D. Ramsey et al.   JOURNAL OF CLINICAL ONCOLOGY

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Innovation in the pharmaceutical industry: New estimates of R&D costs

(2016) Joseph A. DiMasi et al.   JOURNAL OF HEALTH ECONOMICS

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study

(2016) Sabine Vogler et al.   LANCET ONCOLOGY

The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem

(2016) Vinay Prasad et al.   MAYO CLINIC PROCEEDINGS

Use the Bayh-Dole Act to lower drug prices for government healthcare programs

(2016) Alfred B Engelberg et al.   NATURE MEDICINE

State Initiatives to Control Medication Costs — Can Transparency Legislation Help?

(2016) Ameet Sarpatwari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

(2016) H. K. Sanoff et al.   ONCOLOGIST

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

(2016) Andrew Hill et al.   BMJ Open

Cancer Drugs Fund requires further reform

(2016) Richard Grieve et al.   BMJ-British Medical Journal

Cancer Drugs Fund requires further reform

(2016) Richard Grieve et al.   BMJ-British Medical Journal

Generic Drug Approvals Since the 1984 Hatch-Waxman Act

(2016) Ravi Gupta et al.   JAMA Internal Medicine

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient’s Bedside

(2016) Daniel A. Goldstein   JAMA Oncology

Perspectives on Cost and Value in Cancer Care

(2016) Leonard B. Saltz   JAMA Oncology

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

(2016) Hemanth Kumar et al.   JAMA Oncology

Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014

(2016) Stacie B. Dusetzina   JAMA Oncology

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

(2015) V. Prasad et al.   BLOOD

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses

(2015) C. J. Saret et al.   BLOOD

Are high drug prices for hematologic malignancies justified? A critical analysis

(2015) Jagpreet Chhatwal et al.   CANCER

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer

(2015) Daniel A. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

(2015) Daniel A. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

(2015) Rajendra Badwe et al.   LANCET ONCOLOGY

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

(2015) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

The $2.6 Billion Pill — Methodologic and Policy Considerations

(2015) Jerry Avorn   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Five Years of Cancer Drug Approvals

(2015) Sham Mailankody et al.   JAMA Oncology

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice

(2015) Aaron P. Mitchell et al.   Journal of Oncology Practice

Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients

(2014) Vinay Prasad et al.   JOURNAL OF CLINICAL ONCOLOGY

Using a Drug-Safety Tool to Prevent Competition

(2014) Ameet Sarpatwari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Effectiveness Questions in Oncology

(2014) Sham Mailankody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

(2014) Tito Fojo et al.   JAMA Otolaryngology-Head & Neck Surgery

Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications

(2013) Amy P. Abernethy   ANNALS OF INTERNAL MEDICINE

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis

(2013) Scott Ramsey et al.   HEALTH AFFAIRS

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?

(2011) Bhaven N. Sampat et al.   HEALTH AFFAIRS

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

The Role of Public-Sector Research in the Discovery of Drugs and Vaccines

(2011) Ashley J. Stevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

Food Price and Diet and Health Outcomes

(2010) Kiyah J. Duffey   ARCHIVES OF INTERNAL MEDICINE

New £50 million cancer fund already intellectually bankrupt

(2010) The Lancet   LANCET

The importance of new companies for drug discovery: origins of a decade of new drugs

(2010) Robert Kneller   NATURE REVIEWS DRUG DISCOVERY

How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question

(2009) T. Fojo et al.   JNCI-Journal of the National Cancer Institute

Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs

(2009) Peter B. Bach   NEW ENGLAND JOURNAL OF MEDICINE